212 related articles for article (PubMed ID: 30138160)
21. Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review.
Obrișcă B; Jurubiță R; Sorohan B; Iliescu L; Baston C; Bobeică R; Andronesi A; Leca N; Ismail G
Clin Rheumatol; 2019 Dec; 38(12):3677-3687. PubMed ID: 31172367
[TBL] [Abstract][Full Text] [Related]
22. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.
Dammacco F; Lauletta G; Vacca A
Clin Exp Med; 2023 Jun; 23(2):255-272. PubMed ID: 35348938
[TBL] [Abstract][Full Text] [Related]
23. Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.
Gragnani L; Lorini S; Marri S; Basile U; Santarlasci V; Monti M; Madia F; Petraccia L; Stasi C; Marello N; Napodano C; Annunziato F; Zignego AL
Hepatology; 2021 Sep; 74(3):1164-1173. PubMed ID: 33721342
[TBL] [Abstract][Full Text] [Related]
24. Long-term renal function alterations in hepatitis C patients with SVRs: Impacts of therapies and mixed cryoglobulinemia.
Chang ML; Cheng JS; Chen WT; Hsu CW; Chen KH; Chen YC; Chien RN
J Infect Public Health; 2024 Mar; 17(3):486-494. PubMed ID: 38280352
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis.
Rutledge SM; Chung RT; Sise ME
Hemodial Int; 2018 Apr; 22 Suppl 1():S81-S96. PubMed ID: 29694729
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
[TBL] [Abstract][Full Text] [Related]
27. Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
Chowdhury R; Tsen A
Am J Kidney Dis; 2017 Aug; 70(2):301-304. PubMed ID: 28343737
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.
Wiznia LE; Laird ME; Franks AG
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1260-1270. PubMed ID: 28252812
[TBL] [Abstract][Full Text] [Related]
29. Neurological manifestations of chronic hepatitis C.
Heckmann JG; Kayser C; Heuss D; Manger B; Blum HE; Neundörfer B
J Neurol; 1999 Jun; 246(6):486-91. PubMed ID: 10431776
[TBL] [Abstract][Full Text] [Related]
30. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.
Miailhes P; Hartig-Lavie K; Virlogeux V; Pradat P; Diakite M; Uhres AC; Zoulim F; Sarda MN
Clin Microbiol Infect; 2018 Nov; 24(11):1215.e1-1215.e4. PubMed ID: 29870852
[TBL] [Abstract][Full Text] [Related]
31. Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome.
Zignego AL; Marri S; Gragnani L
Minerva Gastroenterol (Torino); 2021 Sep; 67(3):218-226. PubMed ID: 33793154
[TBL] [Abstract][Full Text] [Related]
32. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus.
Cresta P; Musset L; Cacoub P; Frangeul L; Vitour D; Poynard T; Opolon P; Nguyen DT; Golliot F; Piette JC; Huraux JM; Lunel F
Gut; 1999 Jul; 45(1):122-8. PubMed ID: 10369715
[TBL] [Abstract][Full Text] [Related]
33. Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals.
Comarmond C; Cacoub P; Saadoun D
Therap Adv Gastroenterol; 2020; 13():1756284820942617. PubMed ID: 32782479
[TBL] [Abstract][Full Text] [Related]
34. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P
Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
[TBL] [Abstract][Full Text] [Related]
36. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
37. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and incidence of cryoglobulins in hepatitis C virus-related chronic hepatitis patients: a prospective study.
Persico M; De Marino FA; Di Giacomo Russo G; Persico E; Morante A; Palmentieri B; Torella R
Am J Gastroenterol; 2003 Apr; 98(4):884-8. PubMed ID: 12738472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
